BioLineRx's Dr. Geffen will present results from Phase 2b EAGLE trial at Schizophrenia International Research Society (SIRS) Conference , Florence, Italy

April 13, 2010
PDF Version
On Thursday April 15,  Yona Geffen, PhD, from BioLineRX will be presenting "A double-blind placebo control study evaluating the efficacy and safety of BL-1020 , a GABA enhanced antipsychotic for the treatment of schizophrenia" at  the SIRS Conference, "Cognition in Schizophrenia" Session.
Shape
Potential life-changing treatments are on the way

Each molecule in our development pipeline is carefully selected for its potential ability to improve upon the standard of care, delivering maximum value to patients

Discover our Pipeline